Boston Scientific begins WallFlex trial
This article was originally published in Clinica
Executive Summary
A clinical trial to evaluate temporary implantation of Boston Scientific's fully-covered WallFlex biliary stent in the treatment of benign bile duct strictures has been initiated. The 187-patient trial will evaluate the effectiveness of temporary stenting for treating long-term benign biliary strictures, as well as their removal. The study will include patients with bile duct strictures associated with post-liver transplant anastomosis, prior abdominal surgery such as gall bladder removal, and chronic pancreatitis. The stent will remain in the patients for 4-12 months depending on the nature of the stricture, and patients will be followed for five years after stent removal.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.